Team Leader supervising an outstanding team of solid form materials scientists, managing, coaching and developing colleagues to deliver complex solid form nominations. Managed resource and assigned responsibilities.

Manager, Materials Science lead and crystallographer, performing solid form selection. X-ray laboratory coordinator. Delivered multiple complex commercial form nominations, leading combined computational and experimental approaches to underwrite the stability, manufacturability and bioperformance of the API in the drug product.

Materials Science lead and Crystallographer, working with Diamond Light Source to deliver structures for challenging molecules, and with the Cambridge Crystallographic Data Centre as part of the Solid Form Design Centre collaboration.Experimentally and computationally derisked new candidates, authoring several commercial solid form nominations. Led outsourcing activities for programs.

Materials Science lead, representing group to other functions on the project team, working closely with colleagues in chemistry, crystallisation and formulation to secure the solid form and troubleshoot issues.

Used a novel UV probe technique in combination with statistical induction time measurements to study aggregation properties of solutes.By carrying out statistical measurements of nucleation rates, it is possible to elucidate kinetic and thermodynamic parameters describing the nucleation event.UV spectroscopy of solutions close to and above their saturation points allows a theoretical model to be applied, giving information on the aggregation behaviour of these solutions.By combining the information from these two techniques, a greater understanding of the mechanism of crystal nucleation will be developed. Both these techniques are new, and provide rare opportunities for analysing the nucleation state.

Devised and pursued both computational and practical approaches to attempt to link the conformational properties of molecules to their crystal growth, and to understand the impact of impurities in pharmaceutical crystallization.

Oversaw solid state work on compounds across several teams, ensuring selection of the best solid form for development.Developed new ways of working to meet changing needs after a reorganisation.

Carried out solid state risk assessments and screening on new candidate drugs.

Developed, validated and applied cGMP methods for HPLC, GC, dissolution, solution NMR and other analytical techniques.